Диссертация (Разработка методик количественного определения пинолина и его метаболита методом LC/MS/MS), страница 13

– 2013. – Т. 15. – №. 2. –С. 103-105.51.Herraiz T., Galisteo J. Endogenous and dietary indoles: a class ofantioxidants and radical scavengers in the ABTS assay //Free radical research. – 2004. –Т. 38. – №. 3. – С. 323-331.52.His W. On the metabolic products of pyridine //Arch. Ex. Pathol.Pharmakol. – 1887. – Т. 22.

– С. 253-260.53.Ho R. H., Kim R. B. Transporters and drug therapy: implications for drugdisposition and disease //Clinical Pharmacology & Therapeutics. – 2005. – Т. 78. – №.3. – С. 260-277.54.Jaffe M., Cohn R. // Ber. Dtsch. Chem. Ges. – 1887. – Т. 20. – 2311с.55.Jiang X. L., Shen H.

W., Yu A. M. Pinoline may be used as a probe forCYP 2D6 activity //Drug Metabolism and Disposition. – 2009. – Т. 37. – №. 3. – С.443-446.56.Keller W. M. Keller on the Conversion of Benzoic into Hippuric Acid//Provincial medical journal and retrospect of the medical sciences. – 1842. – Т. 4. – №.92. – С.

256.8557.Kim M. et al. Inhibition of the enantioselective oxidative metabolism ofmetoprolol by verapamil in human liver microsomes //Drug metabolism and disposition.– 1993. – Т. 21. – №. 2. – С. 309-317.58.Klingenberg M. Pigments of rat liver microsomes //Archives ofbiochemistry and biophysics. – 1958. – Т. 75.

– №. 2. – С. 376-386.59.Knollmann B. C. (ed.). Goodman & Gilman's the pharmacological basis oftherapeutics. – New York : McGraw-Hill Medical, 2011. – Т. 12. – С. 327-328.60.Labbé L. et al. Effect of gender, sex hormones, time variables andphysiological urinary pH on apparent CYP 2D6 activity as assessed by metabolic ratiosof marker substrates //Pharmacogenetics and Genomics. – 2000.

– Т. 10. – №. 5. – С.425-438.61.Lennard M. S. et al. Oxidation phenotype—a major determinant ofmetoprolol metabolism and response //New England Journal of Medicine. – 1982. – Т.307. – №. 25. – С. 1558-1560.62.Lennard M. S. et al. Oxidation phenotype—a major determinant ofmetoprolol metabolism and response //New England Journal of Medicine. – 1982.

– Т.307. – №. 25. – С. 1558-1560.63.Lewis D. F. V. Essential requirements for substrate binding affinity andselectivity toward human CYP2 family enzymes //Archives of biochemistry andbiophysics. – 2003. – Т. 409. – №. 1. – С. 32-44.64.Lewis D. F. V., Dickins M. Substrate SARs in human P450s //Drugdiscovery today. – 2002. – Т.

7. – №. 17. – С. 918-925.65.Lewis D. F. V., Jacobs M. N., Dickins M. Compound lipophilicity forsubstrate binding to human P450s in drug metabolism //Drug discovery today. – 2004. –Т. 9. – №. 12. – С. 530-537.66.Marandi T. et al. Debrisoquine and S-mephenytoin hydroxylationpolymorphisms in a Russian population living in Estonia //European journal of clinicalpharmacology. – 1997. – Т. 53. – №. 3-4. – С.

257-260.67.March , J. Advanced Organic Chemistry 4th edn // John Wiley & Sons, Inc.– 1992. – C. 553 – 554.8668.Mason H. S. Mechanism of Oxygen Metabolism. Adv. Enzymol. 19, 79–233 (1957).—Cf. ibid. 16, 105 (1955) //Oxidases. Ann. Revs. Biochem. – 1965.

– Т. 34.– С. 595-634..69.Moltke L. L. et al. Multiple Human Cytochromes Contribute toBiotransformation of Dextromethorphan In‐vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A //Journal of pharmacy and pharmacology. – 1998. – Т. 50. – №. 9. –С. 997-1004.70.NeumeisterR.LehrbuchderphysiologischenChemie:mitBerücksichtigung der pathologischen Verhältnisse. – G.

Fischer, 1897.71.Nozawa T. et al. Influence of CYP 2D6 genotype on metoprolol plasmaconcentration and β-adrenergic inhibition during long-term treatment: A comparisonwith bisoprolol //Journal of cardiovascular pharmacology. – 2005. – Т. 46. – №. 5. – С.713-720.72.Omura T. et al. Function of cytochrome P-450 of microsomes //Federationproceedings. – 1965. – Т. 24. – №. 5. – С. 1181.73.Omura T., Sato R. A new cytochrome in liver microsomes //Journal ofBiological Chemistry. – 1962. – Т.

237. – №. 4. – С. PC1375-PC1376.74.Otton S. V. et al. Use of quinidine inhibition to define the role of thesparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human livermicrosomes //Journal of Pharmacology and Experimental Therapeutics. – 1988. – Т.247. – №. 1. – С. 242-247.75.Pähkla R., Harro J., Rägo L. Behavioural effects of pinoline in the ratforced swimming, open field and elevated plus-maze tests //Pharmacological research.

–1996. – Т. 34. – №. 1. – С. 73-78.76.Pedersen R. S., Damkier P., Brosen K. Tramadol as a new probe forcytochrome P450 2D6 phenotyping: a population study //Clinical Pharmacology &Therapeutics. – 2005. – Т. 77. – №. 6. – С. 458-467.77.Poulsen L. et al. The hypoalgesic effect of tramadol in relation to CYP2D6* //Clinical Pharmacology & Therapeutics. – 1996. – Т. 60. – №. 6. – С. 636-644.8778.Qi W. et al. Increased levels of oxidatively damaged DNA induced bychromium (III) and H2O2: protection by melatonin and related molecules //Journal ofpineal research.

– 2000. – Т. 29. – №. 1. – С. 54-61.79.Regårdh C. G., Johnsson G. Clinical pharmacokinetics of metoprolol//Clinical pharmacokinetics. – 1980. – Т. 5. – №. 6. – С. 557-569.80.Rodrigues A. D. Integrated cytochrome P450 reaction phenotyping//Biochem Pharmacol. – 1999. – Т. 57. – С. 465-480.81.Schellens J. H. et al. Lack of pharmacokinetic interaction betweennifedipine, sparteine and phenytoin in man //British journal of clinical pharmacology. –1991. – Т.

31. – №. 2. – С. 175-178.82.Schinkel A. H. et al. P-glycoprotein in the blood-brain barrier of miceinfluences the brain penetration and pharmacological activity of many drugs //Journal ofClinical Investigation. – 1996. – Т. 97. – №. 11. – С. 2517.83.Seelig A., Gottschlich R., Devant R. M. A method to determine the abilityof drugs to diffuse through the blood-brain barrier //Proceedings of the NationalAcademy of Sciences. – 1994. – Т. 91. – №.

1. – С. 68-72.84.Sheridan R. P. et al. Empirical regioselectivity models for humancytochromes P450 3A4, 2D6, and 2C9 //Journal of medicinal chemistry. – 2007. – Т.50. – №. 14. – С. 3173-3184.85.Streetman D. S., Bertino Jr J. S., Nafziger A. N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotypingprobes //Pharmacogenetics and Genomics. – 2000. – Т. 10. – №.

3. – С. 187-216.86.Subrahmanyam V. et al. Identification of cytochrome P-450 isoformsresponsible for cis-tramadol metabolism in human liver microsomes //Drug Metabolismand Disposition. – 2001. – Т. 29. – №. 8. – С. 1146-1155.87.Takashima T. et al. Evaluation of dextromethorphan metabolism usinghepatocytes from CYP 2D6 poor and extensive metabolizers //Drug metabolism andpharmacokinetics. – 2005. – Т. 20. – №. 3.

– С. 177-182.88.Tegeder I., Lötsch J., Geisslinger G. Pharmacokinetics of opioids in liverdisease //Clinical pharmacokinetics. – 1999. – Т. 37. – №. 1. – С. 17-40.8889.Terfloth L., Bienfait B., Gasteiger J. Ligand-based models for the isoformspecificity of cytochrome P450 3A4, 2D6, and 2C9 substrates //Journal of chemicalinformation and modeling. – 2007. – Т.

47. – №. 4. – С. 1688-1701.90.Totah R. A., Rettie A. E. Cytochrome P450 2C8: substrates, inhibitors,pharmacogenetics, and clinical relevance //Clinical Pharmacology & Therapeutics. –2005. – Т. 77. – №. 5. – С. 341-352.91.Trager W. F. et al. Oral anticoagulants //Metabolic Drug Interactions. –2000.

– 748 c.92.Ure A. On gouty concretions, with a new method of treatment //Medico-chirurgical transactions. – 1841. – Т. 24. – С. 30.93.Van Montfoort J. E. et al. Drug uptake systems in liver and kidney//Current drug metabolism. – 2003. – Т. 4. – №. 3. – С. 185-211.94.Von Bahr C. et al. Plasma levels and effects of metoprolol on bloodpressure, adrenergic beta receptor blockade, and plasma renin activity in essentialhypertension //Clinical pharmacology and therapeutics. – 1976. – Т. 20.

– №. 2. – С.130-137.95.Wang P. P. et al. Purification and characterization of six cytochrome P-450isozymes from human liver microsomes //Biochemistry. – 1983. – Т. 22. – №. 23. – С.5375-5383.96.Ward C.. Sumpter, Miller F. M. Heterocyclic compounds with indole andcarbazole systems. – Interscience, 1954.97.WilliamsJ.A.etal.Drug-druginteractionsforUDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typicallyobserved low exposure (AUCi/AUC) ratios //Drug Metabolism and Disposition. – 2004.– Т. 32. – №.

11. – С. 1201-1208.98.Williams R. T. et al. Detoxication mechanisms. The metabolism of drugsand allied organic compounds //Detoxication mechanisms. The metabolism of drugs andallied organic compounds. – 1947.99.Wöhler F. Tiedemann's Z //Physiol. – 1824. – Т. 1. – С. 142.89100.Wöhler F., Frerichs F. T. Concerning the modifications which particularorganic materials undergo in their transition to the urine //Ann Chem Pharm. – 1848. –Т. 63. – С. 335.101.Yap C. W., Chen Y.

Z. Prediction of cytochrome P450 3A4, 2D6, and 2C9inhibitors and substrates by using support vector machines //Journal of chemicalinformation and modeling. – 2005. – Т. 45. – №. 4. – С. 982-992..